Patients pretreated with P2Y12 inhibitors before undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) saw a significant reduction in major cardiac events without increased bleeding risk in a new study of a regional Spanish registry published Monday online.